Latest Conference Articles

March 10th 2019, 1:23am

PER® Miami Breast Cancer Conference

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.

March 9th 2019, 7:27pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

March 9th 2019, 2:44am

PER® Miami Breast Cancer Conference

The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.

March 9th 2019, 2:35am

PER® Miami Breast Cancer Conference

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

March 9th 2019, 1:55am

PER® Miami Breast Cancer Conference

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

March 9th 2019, 1:44am

PER® Miami Breast Cancer Conference

Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.

March 9th 2019, 1:27am

PER® Miami Breast Cancer Conference

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1

March 9th 2019, 12:47am

PER® Miami Breast Cancer Conference

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

March 8th 2019, 9:55pm

PER® Miami Breast Cancer Conference

After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.

March 8th 2019, 9:30pm

PER® Miami Breast Cancer Conference

The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.

March 8th 2019, 8:51pm

PER® Miami Breast Cancer Conference

Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.

March 4th 2019, 4:40am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

March 4th 2019, 12:26am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

March 3rd 2019, 11:36pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

March 3rd 2019, 9:14pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

March 3rd 2019, 4:33am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

March 3rd 2019, 12:17am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

March 2nd 2019, 10:49pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

William G. Wierda, MD, PhD, discusses how CAR T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia.

March 2nd 2019, 8:39pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

March 2nd 2019, 7:16pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.